Compare Archer Aviation Inc (ACHR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer Aviation Inc vs Sana Biotechnology Inc — how do they compare? Archer Aviation Inc trades at $4.85 (market cap $3.76B), while Sana Biotechnology Inc trades at $3.98 (market cap $1.15B). The key difference: Archer Aviation Inc is far larger — about 3.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | SANA | |
|---|---|---|
Market Cap | $3.76B | $1.15B |
Sector | Industrials | Health |
52-Week High | $13.64 | $5.92 |
52-Week Low | $4.68 | $2.68 |
Enterprise Value | $2.11B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
